Iconix Biosciences, Inc

Iconix Biosciences has developed leading products and services that apply novel and proprietary genomic technologies to profile candidate drug compounds in early discovery through to preclinical development, leading to a better understanding of candidate drugs in a faster, more cost-effective manner...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics Vol. 8; no. 4; pp. 401 - 405
Main Authors Fielden, Mark R, Halbert, Donald N
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.04.2007
Subjects
Animals
drug discovery
Drug Industry - methods
Drug Industry - trends
Genomics - methods
Genomics - trends
Humans
mechanism
microarray
preclinical
predictive biomarker
Technology, Pharmaceutical - methods
Technology, Pharmaceutical - trends
Toxicogenetics - methods
Toxicogenetics - trends
toxicogenomics
Online AccessGet full text

Cover

More Information
Summary:Iconix Biosciences has developed leading products and services that apply novel and proprietary genomic technologies to profile candidate drug compounds in early discovery through to preclinical development, leading to a better understanding of candidate drugs in a faster, more cost-effective manner. The toxicology community is embracing this approach to increase the accuracy, sensitivity and speed of toxicity testing. Changing this paradigm will significantly impact the failure rate of late-stage preclinical compounds and provide a compelling return on investment. Through strategic growth and research, the company has identified the factors and is creating the environment that will lead to a '‘tipping point ’ in the pharmaceutical and biotechnology industries, such that toxicogenomics becomes a standard practice in the drug discovery and development process.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1462-2416
1744-8042
DOI:10.2217/14622416.8.4.401